

<i>Interview Summary</i>	Application No.	Applicant(s)
	09/889,793	HAGEMAN ET AL.
	Examiner	Art Unit
	Devesh Khare	1623

All participants (applicant, applicant's representative, PTO personnel):

(1) Devesh Khare. (3) _____.

(2) Philip Dubois. (4) _____.

Date of Interview: 07 January 2005.

Type: a) Telephonic b) Video Conference
c) Personal [copy given to: 1) applicant 2) applicant's representative]

Exhibit shown or demonstration conducted: d) Yes e) No.
If Yes, brief description: _____.

Claim(s) discussed: _____.

Identification of prior art discussed: _____.

Agreement with respect to the claims f) was reached. g) was not reached. h) N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: Claims 28 and 32-34 have been cancelled without prejudice.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.

Examiner's signature, if required

Art Unit: 1623

Applicant's amendments and remarks filed on 10/13/04 are acknowledged. Claims 29 and 31 have been amended. Claims 1-17, 20 and 26-27 have been cancelled.

The rejections of claims 29 and 31 under 35 U.S.C., 112, second paragraph have been overcome through applicants' amendment to the claims.

The examiner withdraws the rejection of claim 29 under obviousness-type double patenting as being unpatentable over US 6,613,367 ('367) in response to applicant's remarks that the '367 patent fail to include fat, riboflavin, thiamine, niacin and zinc in the composition.

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given by Philip Dubois on 01/07/05.

Claims 28 and 32-34 have been cancelled without prejudice.

Claims 18-19, 21-25 and 29-31 are currently pending in this application.

Claims 18-19, 21-25 and 29-31 are allowed.

2. The following is an examiner's statement of reasons for allowance: Claims 18-19, 21-25 and 29-31 are directed to a composition and a method for the treating serotonin- or melatonin-mediated mood or sleep disorders with the said composition which


Art Unit: 1623

comprises carbohydrates, fats and proteins and further comprises folic acid, vitamin B6 and B12 and at least one component selected from the groups consisting of riboflavin, thiamine, niacin and zinc, wherein folic acid is more than 44 µg up to 4000 µg, vitamin B12 more than 0.8 µg up to 2000 µg, vitamin B6 more than 50 µg up to 10,000 µg , is not taught or fairly suggested by the prior art of the record.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

3. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703)308-1235.

Devesh Khare, Ph.D.,J.D.
Art Unit 1623
January 18,2005



JAMES O. WILSON
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600